NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/17/2026 13:04
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization17,397 mln
Float62.11 mln
Earnings Date08/06/2026
EPS
8.61
Stretched
P / E
30.90
Overvalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
3.38
Highly suspicious
1-Year Forecast
299
Modest upside
Relative Strength
34
/ 100
Underperforming
Business Description
Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.
